Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study
Open Access
- 15 February 2021
- Vol. 10 (2), 394
- https://doi.org/10.3390/cells10020394
Abstract
Bilirubin, an endogenous antioxidant, may play a protective role in cancer development. We applied two-sample Mendelian randomization to investigate whether genetically raised bilirubin levels are causally associated with the risk of ten cancers (pancreas, kidney, endometrium, ovary, breast, prostate, lung, Hodgkin’s lymphoma, melanoma, and neuroblastoma). The number of cases and their matched controls of European descent ranged from 122,977 and 105,974 for breast cancer to 1200 and 6417 for Hodgkin’s lymphoma, respectively. A total of 115 single-nucleotide polymorphisms (SNPs) associated (p < 5 × 10−8) with circulating total bilirubin, extracted from a genome-wide association study in the UK Biobank, were used as instrumental variables. One SNP (rs6431625) in the promoter region of the uridine-diphosphoglucuronate glucuronosyltransferase1A1 (UGT1A1) gene explained 16.9% and the remaining 114 SNPs (non-UGT1A1 SNPs) explained 3.1% of phenotypic variance in circulating bilirubin levels. A one-standarddeviation increment in circulating bilirubin (≈ 4.4 µmol/L), predicted by non-UGT1A1 SNPs, was inversely associated with risk of squamous cell lung cancer and Hodgkin’s lymphoma (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.73–0.99, P 0.04 and OR 0.64, 95% CI 0.42–0.99, p 0.04, respectively), which was confirmed after removing potential pleiotropic SNPs. In contrast, a positive association was observed with the risk of breast cancer after removing potential pleiotropic SNPs (OR 1.12, 95% CI 1.04–1.20, p 0.002). There was little evidence for robust associations with the other seven cancers investigated. Genetically raised bilirubin levels were inversely associated with risk of squamous cell lung cancer as well as Hodgkin’s lymphoma and positively associated with risk of breast cancer. Further studies are required to investigate the utility of bilirubin as a low-cost clinical marker to improve risk prediction for certain cancers.Keywords
Funding Information
- Austrian Science Fund (29608)
- Institut National Du Cancer (2016-043)
This publication has 60 references indexed in Scilit:
- Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined SubgroupsJNCI Journal of the National Cancer Institute, 2012
- Genome-wide association study identifies novel loci predisposing to cutaneous melanoma†Human Molecular Genetics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/InhibitorsDrug Metabolism and Disposition, 2010
- Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: Mechanism for the antiviral effects of heme oxygenase?Journal of Hepatology, 2010
- A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33Nature Genetics, 2010
- The association between TA-repeat polymorphism in the promoter region of UGT1A1 and breast cancer risk: a meta-analysisBreast Cancer Research and Treatment, 2010
- Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancerNature Genetics, 2009
- Genome-wide association meta-analysis for total serum bilirubin levelsHuman Molecular Genetics, 2009
- Genetic Polymorphisms in theUGT1A1Gene and Breast Cancer Risk in Greek WomenGenetic Testing, 2007